43
Participants
Start Date
June 9, 2023
Primary Completion Date
June 9, 2027
Study Completion Date
June 9, 2027
IO102/IO103
IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
Nivolumab-Relatlimab
Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
RECRUITING
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RECRUITING
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
RECRUITING
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale
RECRUITING
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
RECRUITING
Lehigh Valley Health Network (Data Collection Only), Allentown
RECRUITING
Hartford Healthcare Alliance (Data Collection Only), Hartford
RECRUITING
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
RECRUITING
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
RECRUITING
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Collaborators (1)
IO Biotech
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER